Transgene Biotek Stock Screener | Share Price & Fundamental Analysis
TRABI
Healthcare Service Provider
Share Price BSE
₹2.56
▼
-0.09 (-3.40%)
As of April 13, 2026, the Transgene Biotek share price (BSE: TRABI) is ₹2.56, down 3.40% from the previous close, with shares trading between ₹2.53 and ₹2.66, and a 52-week range of ₹1.97–₹5.08.
Browse TRABI income statement to support your investment research.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Transgene Biotek Market Cap
₹20.10 Cr.
TRABI P/E Ratio (TTM)
-10.60
Transgene Biotek P/B Ratio
2.18
EPS (TTM)
₹-0.09
Dividend Yield
-
Debt to Equity
1.38
TRABI 52 Week High
₹5.08
Transgene Biotek 52 Week Low
₹1.97
Operating Margin
-120.00%
Profit Margin
-
TRABI Revenue (TTM)
-
EBITDA
-
Net Income
-
Total Assets
₹144.00
Total Equity
₹10.00
Transgene Biotek Share Price History - Stock Screener Chart
Screen TRABI historical share price movements with interactive charts. Analyze price trends and patterns.
Transgene Biotek Company Profile - Fundamental Screener
Screen Transgene Biotek company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for TRABI shares.
Sector
Healthcare Services
Industry
Healthcare Service Provider
Sub-Sector
Healthcare Service Provider
Segment
E
ISIN
INE773D01018
Transgene Biotek Balance Sheet Screener
Screen TRABI balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 144 | 142 | 142 | 147 | 157 | 167 | 177 | 187 | 198 | 313 |
| Current Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Fixed Assets | 8 | 6 | 6 | 11 | 21 | 31 | 41 | 51 | 61 | 141 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 121 | 121 | 121 | 121 | 121 | 120 | 120 | 120 | 128 | 127 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 10 | 11 | 11 | 17 | 22 | 33 | 44 | 52 | 59 | 174 |
| Share Capital | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 |
| Reserves & Surplus | -66 | -65 | -64 | -58 | -54 | -43 | -32 | -23 | -17 | 99 |
Transgene Biotek Income Statement Screener - Profit & Revenue Analysis
Screen Transgene Biotek income statement and profit fundamentals.
Analyze TRABI quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Transgene Biotek share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| EBITDA | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| Operating Profit % | -120.00% | -160.00% | -280.00% | -675.00% | -113.00% | -133.00% | -820.00% | -520.00% | -200.00% | -240.00% | -120.00% | 0.00% | 0.00% | 0.00% | -233.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -1 | -2 | -1 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -1 | -2 | -1 |
| EPS | -0.05 | -0.05 | -0.06 | -0.09 | -0.01 | -0.01 | 0.03 | -0.04 | -0.02 | -0.02 | -0.02 | -0.19 | -0.18 | -0.23 | -0.18 |
Transgene Biotek Cash Flow Screener - Liquidity Fundamentals
Screen TRABI cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1 | 0 | 0 | 0 | 0 | 0 | -2 | -1 | 0 | 7 |
| Investing Activities | -2 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | -7 |
| Financing Activities | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Transgene Biotek Shareholding Pattern Screener
See Transgene Biotek shareholding pattern with promoter, FII, and DII holdings.
Check Transgene Biotek promoter holding and ownership changes for TRABI on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 71.85% | 71.85% | 71.89% | 71.88% | 71.87% | 71.74% | 71.75% | 71.45% |
| Other Holding | 4.51% | 4.51% | 4.48% | 4.48% | 4.50% | 4.62% | 4.61% | 4.92% |
| Shareholder Count | 13,545 | 13,461 | 13,475 | 13,583 | 13,307 | 12,963 | 12,766 | 12,426 |
Transgene Biotek Share Dividend Screener - Share Yield Analysis
Check Transgene Biotek dividend history with payout and yield data.
View Transgene Biotek dividend details including ex-dates and amounts for TRABI stock.
Transgene Biotek Stock Index Membership
See which indices include Transgene Biotek stock.
Check TRABI index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Transgene Biotek Market Events Screener - Corporate Actions
Get Transgene Biotek corporate actions including splits, bonuses, and buybacks.
Check Transgene Biotek stock events that may affect TRABI share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-12-30 | 2026-12-30 | Annual General Meeting | NA | -28.21% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 16.36% |
| 2025-12-07 | 2025-12-07 | Extraordinary General Meeting | NA | 0.00% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 4.28% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | 2.14% |
| 2025-05-07 | 2025-05-07 | Quarterly Result Announcement | NA | -10.03% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 4.20% |
| 2024-12-05 | 2024-12-05 | Annual General Meeting | NA | 0.74% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -3.82% |
| 2023-12-30 | 2023-12-30 | Annual General Meeting | NA | 58.94% |
Transgene Biotek Competitors Screener - Peer Comparison
Screen TRABI competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 23,454 | 44.08 | 2,555 | 11.28% | 492 | 60.71 |
| Vijaya Diagnostic Centre | 10,055 | 63.10 | 700 | 23.06% | 144 | 62.23 |
| Metropolis Healthcare | 9,644 | 57.32 | 1,346 | 10.64% | 146 | 58.88 |
| Thyrocare Technologies | 6,335 | 46.76 | 702 | 20.80% | 91 | 60.09 |
| Nephrocare Health Services | 5,649 | 78.04 | 770 | 33.97% | 67 | 56.24 |
| Krsnaa Diagnostics | 1,946 | 24.10 | 743 | 16.70% | 78 | 50.38 |
| Suraksha Diagnostic | 1,437 | 44.50 | 256 | 15.11% | 31 | 60.86 |
| One Global Service Provider | 1,165 | 18.72 | 148 | 134.60% | 19 | 52.94 |
| 3B BlackBio DX | 1,049 | 18.04 | 112 | 28.72% | 48 | 44.85 |
| Sastasundar Ventures | 859 | 29.47 | 1,171 | -18.47% | -134 | 43.80 |
Transgene Biotek Company Announcements - News Screener
Screen TRABI latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-24 | Closure of Trading Window | - |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-13 | Dear Sir/Madam This Has Reference To Our Letter Dated January 28 2026. 1) The Board Has Considered And Approved The Unaudited Consolidated & Stand-Alone Financial Results Of The Company For The Quarter Ended 31.12.2025 In Accordance With The Indian | - |
| 2026-02-13 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-02-03 | Declaration Under Clause 36 Of Listing Agreement With BSE PROHIBITORY ORDER NO. RRD/SRO/1166/2026/1 - SEBI | - |
| 2026-01-28 | Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday 13Th February 2026 | - |
| 2026-01-12 | Statement Of Deviation & Variation | - |
| 2026-01-12 | Compliance-57 (5) : intimation after the end of quarter | - |
| 2026-01-12 | Compliance-57 (4) : Prior intimation to the beginning of the quarter | - |
| 2026-01-12 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-01-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-30 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2025-12-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2025-12-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2025-12-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-12-20 | Closure of Trading Window | - |
| 2025-12-05 | Intimation Of Book Closure And Cut -Off Date For The 35Th Annual General Meeting Of Transgene Biotek Limited With Reference To The Subject Cited This Is To Inform That The Register Of Members And The Share Transfer Books Of The Company Will Remain | - |
| 2025-12-05 | Reg. 34 (1) Annual Report. | - |
| 2025-11-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-14 | Un-Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30 2025. (Copy Enclosed) | - |